Eckert & Ziegler stock trades 33.41 percent below yearly high?

Published on 09/25/2026 at 17:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock carries a EUR 23 Berenberg target from August 26, 2026. First-half revenue reached EUR 149.3 million while adjusted EBIT fell 6 percent.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) closed at EUR 12.16 on Xetra on September 25, 2026, leaving the stock 33.41 percent below its 52-week high of EUR 18.26. The latest market level puts execution against the company forecast at the center of the investment case.

Price sits below yearly high

The closing price fell EUR 0.01, or 0.08 percent, from the previous close of EUR 12.17. Xetra trading covered EUR 12.09 to EUR 12.31, with 46,417 shares changing hands and market capitalization at EUR 760.93 million on September 25, 2026.

The stock remained only 1.25 percent above its 52-week low of EUR 12.01, creating a clear numerical contrast with the 33.41 percent gap to the yearly high. For investors, the distance from both ends of the range matters because the share price is close to the lower boundary while the company continues to carry a full-year operating target.

H1 figures test guidance

According to Parqet, Eckert & Ziegler generated EUR 149.3 million in revenue in the first half of 2026, while adjusted EBIT reached EUR 33.3 million, 6 percent below the prior-year level. The same report states that management confirmed 2026 guidance of EUR 320 million in sales and EUR 80 million in EBIT.

The arithmetic leaves EUR 170.7 million of guided sales for the second half and EUR 46.7 million of guided EBIT. That comparison makes delivery timing and segment performance more important than the annual targets alone, particularly because the first-half adjusted EBIT figure represents 41.63 percent of the EUR 80 million full-year goal.

Berenberg keeps EUR 23 target

On August 26, 2026, MarketScreener reported that Berenberg maintained its Buy rating and EUR 23 price target after the half-year figures. The target stands EUR 10.84 above the September 25 closing price, or 89.14 percent higher under the price-target comparison formula.

The rating therefore provides a quantified counterpoint to the market range, but it does not remove the operating hurdle implied by the second-half guidance requirement. Eckert & Ziegler operates in medical and isotope products, supplying isotope technology for medical, scientific, and industrial applications, according to its investor relations page.

Next report is scheduled

MarketScreener lists November 12, 2026, as the reporting date for third-quarter 2026 results. That date is the next scheduled checkpoint for the sales and adjusted EBIT path laid out for the full year.

Closing price stands below high

Eckert & Ziegler stock closed at EUR 12.16 on Xetra on September 25, 2026, with a 52-week range of EUR 12.01 to EUR 18.26 and market capitalization of EUR 760.93 million.